Mesenchymal stem cells: biology and potential clinical uses.

By R. Deans, A. Moseley. Experimental Hematology, 2000

1,476 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/fdc796fa648af4e5b58dbb5af40c6df4807d80a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. A. Caplan
2. O. Ringdén
3. S. Bose
4. N. Singer

In Hematology

1. A. Caplan
2. O. Ringdén

In Pulmonary and Respiratory Medicine

1. A. Caplan

Citations in the corpus

• Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. (2002, background): “and Fas ligand; they do not express B7-1, B7-2, CD40, or CD40L [4,5,9].”
• T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. (2005, background): “MSCs also express adhesion molecules such as ICAM-1/LFA-1 [4, 6] that have costimulatory properties [13] which could participate in T cell priming and interfere with the induction of tolerance.”
• Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells (2005, positive): “Similar properties were previously reported for bone marrow mesenchymal stem cells (BM-MSCs), which have been extensively studied (Lazarus et al, 1995; Pittenger et al, 1999; Deans & Moseley, 2000; Jorgensen et al, 2003).”
• Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. (2009, result): “These observations are in line with recently published phenotypic expression patterns of hMSC (29, 30).”
• Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. (2001, methodology): “Thus transplantation of bone marrow MSC may provide a new method for treatment of osteoporosis, arthritis, periodontal diseases, intrinsic muscular dystrophies, cardiac diseases, and degenerative nerve diseases (5).”
• HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. (2003, background): “1016/S0301-472X(03)00110-3 MSC express intermediate levels of human leukocyte antigen (HLA) major histocompatibility complex (MHC) class I molecules and negligibly low levels of HLA class II and Fas ligand; they do not express the costimulatory molecules B7-1, B7-2, CD40, or CD40L [3,9,10].”